Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05601752 |
| Title | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) |
| Acronym | SURPASS-3 |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Adaptimmune |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | GBR | FRA | ESP | CAN |